Cargando…

Procalcitonin as marker for bacterial coinfection among adult COVID-19 patients in a tertiary-care hospital in the Philippines

Background: Antimicrobials are often given to patients with COVID-19 despite the absence of a bacterial coinfection. Procalcitonin (PCT), when elevated, often indicates the presence of a bacterial infection and is used to guide empiric antibiotic therapy. We sought to determine the utility of PCT an...

Descripción completa

Detalles Bibliográficos
Autores principales: Pesebre, Angelie Lorraine, Abad, Cybele Lara, Francisco, Jan Jorge, Ong, Justin Allister
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614952/
http://dx.doi.org/10.1017/ash.2022.73
_version_ 1784820309193392128
author Pesebre, Angelie Lorraine
Abad, Cybele Lara
Francisco, Jan Jorge
Ong, Justin Allister
author_facet Pesebre, Angelie Lorraine
Abad, Cybele Lara
Francisco, Jan Jorge
Ong, Justin Allister
author_sort Pesebre, Angelie Lorraine
collection PubMed
description Background: Antimicrobials are often given to patients with COVID-19 despite the absence of a bacterial coinfection. Procalcitonin (PCT), when elevated, often indicates the presence of a bacterial infection and is used to guide empiric antibiotic therapy. We sought to determine the utility of PCT and the optimal cutoff value of PCT among patients with COVID-19. Methods: We retrospectively reviewed all COVID-19 confirmed ca-ses hospitalized in our institution from March to December 2020. Of 729 cases, we included 403 (55.3%) who had baseline PCT and blood or respiratory tract specimens (eg, sputum, endotracheal aspirate) within 48 hours of admission. Participants were classified according to PCT levels and COVID-19 severity. A receiver operating characteristic (ROC) curve analysis was performed. The area under the curve (AUC) obtained was used to compute the possible optimal cutoff value using the Youden index. A χ(2) test was used to define association between groups according to the characteristics of variables. Results: Of a total cohort of 403, 245 (57%) were male, with an overall median age of 60 years (range, 22–94). Overall, 28 presented with mild COVID-19, 194 presented with moderate COVID-19, and 181 presented with severe or critical COVID-19. Moreover, 363 (90%) were given antibiotics. Of 28 with mild COVID-19, 22 (79%) received empiric antibiotics. The rate of bacterial coinfection was high at 28% (113 of 403). Klebsiella pneumoniae was the most commonly identified microorganism: 52 (19.5%) of 266 patients. Based on the ROC curve, the optimal cutoff for PCT was 4.72 ng/mL, with 97% specificity and only 6% sensitivity. Only 17 participants had PCT > 4.72 ng/mL. Of these, 1 was mild, 5 were moderate COVID-19, 8 had severe COVID-19, and 3 had critical COVID-19; all received antibiotic therapy. Conclusions: In our cohort, the rate of bacterial coinfection was high. A PCT of >4.72 ng/mL increased the likelihood of a coinfection. However, PCT had poor sensitivity and may not detect the presence of bacterial coinfection, especially when used alone. Serial PCT monitoring, its use in conjunction with other markers, or as a prognostic tool, need to be explored further. Funding: None Disclosures: None
format Online
Article
Text
id pubmed-9614952
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-96149522022-10-29 Procalcitonin as marker for bacterial coinfection among adult COVID-19 patients in a tertiary-care hospital in the Philippines Pesebre, Angelie Lorraine Abad, Cybele Lara Francisco, Jan Jorge Ong, Justin Allister Antimicrob Steward Healthc Epidemiol Covid-19 Background: Antimicrobials are often given to patients with COVID-19 despite the absence of a bacterial coinfection. Procalcitonin (PCT), when elevated, often indicates the presence of a bacterial infection and is used to guide empiric antibiotic therapy. We sought to determine the utility of PCT and the optimal cutoff value of PCT among patients with COVID-19. Methods: We retrospectively reviewed all COVID-19 confirmed ca-ses hospitalized in our institution from March to December 2020. Of 729 cases, we included 403 (55.3%) who had baseline PCT and blood or respiratory tract specimens (eg, sputum, endotracheal aspirate) within 48 hours of admission. Participants were classified according to PCT levels and COVID-19 severity. A receiver operating characteristic (ROC) curve analysis was performed. The area under the curve (AUC) obtained was used to compute the possible optimal cutoff value using the Youden index. A χ(2) test was used to define association between groups according to the characteristics of variables. Results: Of a total cohort of 403, 245 (57%) were male, with an overall median age of 60 years (range, 22–94). Overall, 28 presented with mild COVID-19, 194 presented with moderate COVID-19, and 181 presented with severe or critical COVID-19. Moreover, 363 (90%) were given antibiotics. Of 28 with mild COVID-19, 22 (79%) received empiric antibiotics. The rate of bacterial coinfection was high at 28% (113 of 403). Klebsiella pneumoniae was the most commonly identified microorganism: 52 (19.5%) of 266 patients. Based on the ROC curve, the optimal cutoff for PCT was 4.72 ng/mL, with 97% specificity and only 6% sensitivity. Only 17 participants had PCT > 4.72 ng/mL. Of these, 1 was mild, 5 were moderate COVID-19, 8 had severe COVID-19, and 3 had critical COVID-19; all received antibiotic therapy. Conclusions: In our cohort, the rate of bacterial coinfection was high. A PCT of >4.72 ng/mL increased the likelihood of a coinfection. However, PCT had poor sensitivity and may not detect the presence of bacterial coinfection, especially when used alone. Serial PCT monitoring, its use in conjunction with other markers, or as a prognostic tool, need to be explored further. Funding: None Disclosures: None Cambridge University Press 2022-05-16 /pmc/articles/PMC9614952/ http://dx.doi.org/10.1017/ash.2022.73 Text en © The Society for Healthcare Epidemiology of America 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Covid-19
Pesebre, Angelie Lorraine
Abad, Cybele Lara
Francisco, Jan Jorge
Ong, Justin Allister
Procalcitonin as marker for bacterial coinfection among adult COVID-19 patients in a tertiary-care hospital in the Philippines
title Procalcitonin as marker for bacterial coinfection among adult COVID-19 patients in a tertiary-care hospital in the Philippines
title_full Procalcitonin as marker for bacterial coinfection among adult COVID-19 patients in a tertiary-care hospital in the Philippines
title_fullStr Procalcitonin as marker for bacterial coinfection among adult COVID-19 patients in a tertiary-care hospital in the Philippines
title_full_unstemmed Procalcitonin as marker for bacterial coinfection among adult COVID-19 patients in a tertiary-care hospital in the Philippines
title_short Procalcitonin as marker for bacterial coinfection among adult COVID-19 patients in a tertiary-care hospital in the Philippines
title_sort procalcitonin as marker for bacterial coinfection among adult covid-19 patients in a tertiary-care hospital in the philippines
topic Covid-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614952/
http://dx.doi.org/10.1017/ash.2022.73
work_keys_str_mv AT pesebreangelielorraine procalcitoninasmarkerforbacterialcoinfectionamongadultcovid19patientsinatertiarycarehospitalinthephilippines
AT abadcybelelara procalcitoninasmarkerforbacterialcoinfectionamongadultcovid19patientsinatertiarycarehospitalinthephilippines
AT franciscojanjorge procalcitoninasmarkerforbacterialcoinfectionamongadultcovid19patientsinatertiarycarehospitalinthephilippines
AT ongjustinallister procalcitoninasmarkerforbacterialcoinfectionamongadultcovid19patientsinatertiarycarehospitalinthephilippines